Highlights on Novel Technologies for the Detection of Antibodies to Ro60, Ro52, and SS-B

Table 2

Qualitative agreements between QUANTA Flash and BioPlex assays.

(a)

All patients (𝑛=241)	BioPlex 2200 Ro52			Percent agreement; (95% confidence interval)
	Positive	Negative	Total
QUANTA Flash Ro52
Positive	50	11	61	Pos agreement = 100.0% (92.9–100.0%)
Negative	0	180	180	Neg agreement = 94.2% (89.9–97.1%)
Total	50	191	241	Total agreement = 95.4% (92.0–97.7%)
				kappa = 0.87 (95% CI 0.80–0.95)

(b)

All patients (𝑛=241)	BioPlex 2200 Ro60			Percent agreement; (95% confidence interval)
	Positive	Negative	Total
QUANTA Flash Ro60
Positive	80	0	80	Pos agreement = 96.4% (89.8–99.2%)
Negative	3	158	161	Neg agreement = 100.0% (97.7–100.0%)
Total	83	158	241	Total agreement = 98.8% (96.4–99.7%)
				kappa = 0.97 (95% CI 0.94–1.00)

(c)

All patients (𝑛=241)	BioPlex 2200 SS-B			Percent agreement; (95% confidence interval)
	Positive	Negative	Total
QUANTA Flash SS-B
Positive	26	3	29	Pos agreement = 60.5% (44.4–75.0%)
Negative	17	195	212	Neg agreement = 98.5% (95.6–99.7%)
Total	43	198	241	Total agreement = 91.7% (87.5–94.9%)
				kappa = 0.68 (95% CI 0.55–0.81)